Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.85 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1176879 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL59830 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL11554769 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL11584070 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL11559655 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL25148109 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| Morpholine SCHEMBL8649532 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL7747664 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL111814 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL897208 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119680405-B | Small-aperture polyamide ultrafiltration membrane and preparation method thereof | 湖南澳维科技股份有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-119680405-A | Small-aperture polyamide ultrafiltration membrane and preparation method thereof | 湖南澳维科技股份有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-119601698-A | Microporous layer, gas diffusion layer, method for producing the same, membrane electrode, and fuel cell | 佛山绿动氢能科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-118653152-B | Acidic copper etching solution and preparation method thereof | 合肥中聚和成电子材料有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-118653152-A | Acidic copper etching solution and preparation method thereof | 合肥中聚和成电子材料有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-118027586-A | Composite, microporous membrane, ion exchange membrane, and preparation methods and applications thereof | 国家电投集团氢能科技发展有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-117659668-A | Low-temperature heat-curable resin composition, anisotropic conductive film, and connection structure | 常州德创高新材料科技有限公司 | 2024-03-08 | — | — | CN | claimed |
| US-11870051-B2 | Method of improving fast-chargeability of a lithium-ion battery | GLOBAL GRAPHENE GROUP, INC. (US) | 2024-01-09 | — | — | US | claimed |
| CN-117181019-A | Nitrogen-containing hybrid macrocyclic cycloparaffin polyamide composite membrane, and preparation method and application thereof | 天津大学 | 2023-12-08 | — | — | CN | claimed |
| US-10098974-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2018-10-16 | — | — | US | claimed |
| US-5948906-A | CROWN ETHERS THAT CONTAIN AT LEAST ONE CORE NITROGEN THAT ARE LINKED VIA THE CORE NITROGEN(S) TO AT LEAST ONE FLUOROPHORE THAT CONTAINS AN ADDITIONAL HETEROAROMATIC LIGANDING THE CENTER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-07 | — | — | US | claimed |
| US-5702804-A | Recording sheets | XEROX CORPORATION (US) | 1997-12-30 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0369733-B1 | Fluorescent indicator dyes for alkali metal cations, their preparation and use | UNIV CALIFORNIA (US) | 1996-02-21 | — | — | EP | claimed |
| EP-0369733-A2 | Fluorescent indicator dyes for alkali metal cations, their preparation and use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1990-05-23 | — | — | EP | claimed |
| US-4435362-A | REAGENT LAYER CONTAINING POTASSIUM SODIUM TARTARATE, A CUPRIC SALT | FUJI SHASHIN FILM KABUSHIKI KAISHA (JP) | 1984-03-06 | — | — | US | claimed |
| US-3966766-A | CHELATING AGENTS | SCHERING CORPORATION (US) | 1976-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098974-B2 | Catalytic radiofluorination | ARSA, STS, KCNK18 | MEN1 3204/4885KMT2A 319/4885GAA 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.